References on the Administration of Chemotherapeutic Agents Using ALZET^® Osmotic Pumps

1. Actinomycin

P1379 Kanje,M., Lundborg,G., Edstrom,A. A new method for studies of the effects of locally applied drugs on peripheral nerve regeneration in vivo. Brain Research 1988; 439(--):116-121. >>> Actinomycin D; Cycloheximide; Mitomycin C; Vinblastine; Ringer's solution; CSF/CNS (sciatic nerve); rat; 2001; 2002; 3, 4, 6 days; mp connected to silicone cuff; functionality of mp verified in vivo with dye; tissue perfusion.

top of page

2. Angiostatin

P8109 Dirkx,A.E.M., Egbrink,M.G.A.O., Castermans,K., van der Schaft,D.W.J., Thijssen,V.L.J.L., Dings,R.P.M., Kwee,L., Mayo,K.H., Wagstaff,J., Steege,J.C.A.B., Griffioen,A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; 2 weeks; 7, 11 days; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

P6632 Vogten,J.M., Drixler,T.A., te Velde,E.A., Schipper,M.E., van Vroonhoven,T.J.M.V., Voest,E.E., Rinkes,I.H.M.B. Angiostatin inhibits experimental liver fibrosis in mice. International Journal of Colorectal Disease 2004; 19(-4-):387-394. >>> Angiostatin; PBS; SC; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; no stress (see pg. 389).

P6134 Reijneveld,J.C., Taphoorn,M.J.B., Kerckhaert,O.A.J., Drixler,T.A., Boogerd,W., Voest,E.E. Angiostatin prolongs the survival of mice with leptomeningeal metastases. European Journal of Clinical Investigation 2003; 33(-1-):76-81. >>> Angiostatin; Water, distilled; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; cancer (melanoma); angiogenesis inhibitor; "angiostatin was administered through a continuous infusion...the continuous administration of angiogenesis inhibitors has greater therapeutic efficacy then the more commonly used twice-daily injections." p. 80.

P5342 Velde,E.A.T., Vogten,J.M., Gebbink,M.F.G.B., van Gorp,J.M., Voest,E.E., Rinkes,I.H.M.B. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. British Journal of Surgery 2002; 89(-10-):1302-1309. >>> Angiostatin; SC; Mice; 2001; ; Cancer; angiogenesis inhibitor.

P5052 te Velde,E.A., Voest,E.E., van Gorp,J.M., Verheem,A., Hagendoorn,J., Gebbink,M.F., Rinkes,I.H.B. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. ANNALS OF SURGICAL ONCOLOGY 2002; 9(-3-):303-309. >>> Angiostatin; PBS; SC; mice; 2001; 4-7 days; controls received mp w/ vehicle; stability by mouse cornea neovascularization assay (p. 304); cancer; wound healing; angiogenesis inhibitor.

P4657 Drixler,T.A, Rinkes,I.H.M.B, Ritchie,E.D, van Vroonhoven,T.J.M.V, Gebbink,M.F.B.G, Voest,E.E. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy.. Cancer Research 2000; 60(--):1761-1765. >>> Angiostatin; PBS; SC; mice; 2001; 2002; 7, 14 days; Controls received mp w/ vehicle; dose-response (p. 1763); comparison of SC injections vs. mp; half-life (p. 1761); cancer; angiogenesis inhibitor; this study shows that continuous administration of angiostatin significantly improves inhibition of angiogenesis and tumor growth supression compared to injections.

top of page

3. Ara-C

Q0928 Mak,G., Enwere,E., Gregg,C., Pakarainen,T., Pautanen,M., Huhtaniemi,I., Weiss,S. Male pheromone-stimulated neurogenesis in the adultfemale brain: possible role in mating behavior. Nature Medicine 2008; 10(-8-):1003-1011. >>> Luteinizing hormone; ara-C; Saline; SC; CSF/CNS; Mice; 1007D; 2 days; Controls received mp w/ vehicle; animal info (8-10 wks old, female, CD1).

Q0743 Dutheil,S., Brezun,J.M., Leonard,J., Lacour,M., Tighilet,B. NEUROGENESIS AND ASTROGENESIS CONTRIBUTION TO RECOVERY OF VESTIBULAR FUNCTIONS IN THE ADULT CAT FOLLOWING UNILATERAL VESTIBULAR NEURECTOMY: CELLULAR AND BEHAVIORAL EVIDENCE. Neuroscience 2009; 164(-4-):1444-1456. >>> Ara-C; CSF/CNS (fourth ventricle); Cat; 30 days; Controls received mp w/ saline; animal info (adult, domestic, 3-5 kg).

Q0713 Moreno,M.M., Linster,C., Escanilla,O., Sacquet,J., Didier,A., Mandairon,N. Olfactory perceptual learning requires adult neurogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2009; 106(-42-):17980-17985. >>> Ara-C; Saline; CSF/CNS; Mice; 21 days; Controls received mp w/ vehicle; animal info (adult, male, C57BL/6J, 8 weeks old).

Q0681 Gobeske,K.T., Das,S., Bonaguidi,M.A., Weiss,C., Radulovic,J., Disterhoft,J.F., Kessler,J.A. BMP Signaling Mediates Effects of Exercise on Hippocampal Neurogenesis and Cognition in Mice. PLoS One 2009; 4(-10-):U104-U125. >>> Noggin; ara-C; CSF/CNS; Mice; 1002; 14 days; Controls received mp w/ vehicle; animal info (adult, male, NSE-noggin, NSE-BMP4); "Cannula placement and pump integrity were confirmed in all cases." pg e7507.

Q0642 Piccin,D., Morshead,C.M. Wnt Signaling Regulates Symmetry of Division of Neural Stem Cells in the Adult Brain and in Response to Injury. Stem Cells 2011; 29(-3-):528-538. >>> SB216763; secreted frizzled-related protein 2; Ara-C; DMSO; saline, sterile physiological; CSF/CNS; Mice; 1007D; 4, 6 days; Controls received mp w/ vehicle; animal info (BAT-gal, C57Bl/6, CD1, 8-12 wks old).

Q0549 Giachino,C., Taylor,V. Lineage analysis of quiescent regenerative stem cells in the adult brain by genetic labelling reveals spatially restricted neurogenic niches in the olfactory bulb. European Journal of Neuroscience 2009; 30(-1-):9-24. >>> Ara-C; Saline; CSF/CNS (subventricular zone); Mice; 1007D; 6 days; Controls received mp w/ vehicle; animal info (nestin::CreERT2 Tg, adult, 3 mo old); ALZET brain infusion kit 2 used.

Q0465 Breton-Provencher,V., Lemasson,M., Peralta,MR III, Saghatelyan,A. Interneurons Produced in Adulthood Are Required for the Normal Functioning of the Olfactory Bulb Network and for the Execution of Selected Olfactory Behaviors. Journal of Neuroscience 2009; 29(-48-):15245-15257. >>> Ara-C; Saline; CSF/CNS; Mice; 1004; 28 days; Controls received mp w/ vehicle; animal info (C57BL/6J, male); oxygenated artificial CSF formula, pg 15246; behavioral testing (object recognition, novelty suppressed feeding behavior, tail suspension, odor detection threshold, odor discrimination, long term odor-associative memory, olfactory short-term memory).

Q0412 Yamauchi,T., Tatsumi,K., Makinodan,M., Kimoto,S., Toritsuka,M., Okuda,H., Kishimoto,T., Wanaka,A. Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus. NEUROCHEMISTRY INTERNATIONAL 2010; 57(-5-):565-571. >>> Ara-C; CSF/CNS; Mice; 1002; 4 weeks; Controls received mp w/aCSF; animal info (Female C57BL/6J, 10 wks old); pumps replaced after 2 weeks; ALZET brain infusion kit 3 used; 2-day delayed infusion by filling vinyl tubing with artificial CSF.

Q0397 Aguirre,A., Rubio,M.E., Gallo,V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature 2010; 467(-7313-):323-U101. >>> Ara-C; epidermal growth factor; Saline; CSF/CNS (surface); CSF/CNS; Mice; 5, 6 days; Controls received mp w/vehicle; animal info (Cnp-hEGFR); incorrectly stated model 1007.

Q0391 Nam,H.S., Benezra,R. High Levels of Id1 Expression Define B1 Type Adult Neural Stem Cells. Cell Stem Cell 2009; 5(-5-):515-526. >>> Ara-C; CSF, artificial; CSF/CNS; Mice; 6 days; Animal info (GFAP:LSL-GFP, 6 wks old); 6 days; ALZET brain infusion kit used.

Q0241 Im,S.H., Yu,J.H., Park,E.S., Lee,J.E., Kim,H.O., Park,K.I., Kim,G.W., Park,C.I., Cho,S.R. INDUCTION OF STRIATAL NEUROGENESIS ENHANCES FUNCTIONAL RECOVERY IN AN ADULT ANIMAL MODEL OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY. Neuroscience 2010; 169(-1-):259-268. >>> Brain-derived neurotrophic factor; epidermal growth factor; ara-C; CSF/CNS; Mice; 1002; 2 weeks; Controls received mp w/ PBS; ALZET brain infusion kit 3 used; animal info (ICR, 6 wks old); behavioral testing (rotarod performance, forelimb-use asymmetry test).

Q0180 Pierce,A.A., Xu,A.W. De Novo Neurogenesis in Adult Hypothalamus as a Compensatory Mechanism to Regulate Energy Balance. Journal of Neuroscience 2010; 30(-2-):723-730. >>> Ara-C; uridine, 5' bromodeoxy; CSF, artificial; BSA; CSF/CNS; Mice (transgenic); 2006; 4, 6 weeks; Controls received mp w/ vehicle; ALZET brain infusion kit; animal info (male, wt, AgRP-Tfam, 12 weeks old); functionality of mp verified by residual volume; cannula placement confirmed histologically.

Q0124 Imayoshi,I., Sakamoto,M., Yamaguchi,M., Mori,K., Kageyama,R. Essential Roles of Notch Signaling in Maintenance of Neural Stem Cells in Developing and Adult Brains. Journal of Neuroscience 2010; 30(-9-):3489-3498. >>> Ara-C; Ringer's solution; albumin, mouse serum; CSF/CNS; Mice; 1002; 7 days; Animal info (C57BL/6:ICR, Rbpj-conditional mutant, 2 months old); cytosine-B-D-arabinofuranoside.

Q0021 Li,B., Piao,C.S., Liu,X.Y., Guo,W.P., Xue,Y.Q., Duan,W.M., Gonzalez-Toledo,M.E., Zhao,L.R. Brain self-protection: The role of endogenous neural progenitor cells in adult brain after cerebral cortical ischemia. Brain Research 2010; 1327(-;-):91-102. >>> Ara-C; Saline; CSF/CNS; Mice; rat; 1007D; 7 days; Controls received mp w/vehicle; animal info (male, C57BL, 3 months old; male, SHR, 3-5 months old; CCAO, MCAO); ischemia (cerebral).

P9988 Sultan,S., Mandairon,N., Kermen,F., Garcia,S., Sacquet,J., Didier,A. Learning-dependent neurogenesis in the olfactory bulb determines long-term olfactory memory. FASEB Journal 2010; 24(-7-):2355-2363. >>> Ara-C; Saline; CSF/CNS; Mice; 2004; ; Controls received mp w/ vehicle; animal info (adult, C57BL/6).

P9820 Lau,B.W.M., Yau,S.Y., Lee,T.M.C., Ching,Y.P., Tang,S.W., So,K.F. Intracerebroventricular infusion of cytosine-arabinoside causes prepulse inhibition disruption. NeuroReport 2009; 20(-4-):371-377. >>> Ara-C; CSF/CNS; Rat; 3-13 days; Controls received mp w/ saline; no stress (see pg. 373); animal info (male, Sprague Dawley, 260-290 g.); behavioral testing (prepulse inhibition).

P9755 Cheng,L.C., Pastrana,E., Tavazoie,M., Doetsch,F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nature Neuroscience 2009; 12(-4-):399-408. >>> Oligonucleotide, antisense; Ara-C; Saline; CSF/CNS; Mice; 1007D; 12, 14 days; Pumps replaced after 6 days; antisense (miR-124); animal info (2 months old, CD-1); brain tissue distribution.

P9583 Sumner,J.P., Shapiro,E.M., Maric,D., Conroy,R., Koretsky,A.P. In vivo labeling of adult neural progenitors for MRI with micron sized particles of iron oxide: Quantification of labeled cell phenotype. NEUROIMAGE 2009; 44(-3-):671-678. >>> Ara-C; CSF/CNS; Rat; 2002; 2 weeks; Animal info (6 wks old, Sprague-Dawley).

P9246 Alonso,M., Ortega-Perez,I., Grubb,M.S., Bourgeois,J.P., Charneau,P., Lledo,P.M. Turning Astrocytes from the Rostral Migratory Stream into Neurons: A Role for the Olfactory Sensory Organ. Journal of Neuroscience 2008; 28(-43-):11089-11102. >>> Ara-C; Saline; CSF/CNS; Mice; 1007D; 6 days; Controls received mp w/ vehicle; animal info (C57BL/6, 2 months old).

P9237 Galvao,R.P., Garcia-Verdugo,J.M., varez-Buylla,A. Brain-Derived Neurotrophic Factor Signaling Does Not Stimulate Subventricular Zone Neurogenesis in Adult Mice and Rats. Journal of Neuroscience 2008; 28(-50-):13368-13383. >>> Ara-C; brain-derived neurotrophic factor; Saline; BSA; CSF/CNS; Rat; mice; 1007D; 2002; 6, 14 days; Controls received mp w/ vehicle; functionality of mp verified by weight loss due to BDNF's appetite suppression (p. 13377), residual volume; stability verified by testing activity of residual BDNF volume after 14 days/37 degrees Celsius; brain tissue distribution; peptides; post op. care (Buprenorphine); animal info (male, Sprague Dawley, 250 g., male CD-1 3 mo old); mp/cannula placement visually confirmed after brain sectioning.

P8794 Louis,S.A., Rietze,R.L., Deleyrolle,L., Wagey,R.E., Thomas,T.E., Eaves,A.C., Reynolds,B.A. Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay. Stem Cells 2008; 26(-4-):988-996. >>> Epidermal growth factor; ara-c; Saline; CSF/CNS; Mice; 1007D; 7 days; Controls received mp w/ vehicle; cyanoacrylate adhesive; animal info (adult, C57BL/6).

P8626 Cho,S.R., Benraiss,A., Chmielnicki,E., Samdani,A., Economides,A., Goldman,S.A. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. Journal of Clinical Investigation 2007; 117(-10-):2889-2902. >>> Ara-C; Saline; CSF/CNS; Mice (transgenic); 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; ALZET brain infusion kit 3 used; animal info (R6/2, wt, 5-9 weeks old); neurodegenerative (Huntington's disease).

P8507 Stranahan,A.M., Arumugam,T.V., Cutler,R.G., Lee,K., Egan,J.M., Mattson,M.P. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat.Neurosci. 2008/3; 11(-3-):309-317. >>> Ara-C; CSF/CNS; Mice; 1002; ; Diabetes; animal info (2 months old, wild-type); Ara-C is an anti-mitotic drug.

P8464 Zhao,M., Momma,S., Delfani,K., Carlen,M., Cassidy,R.M., Johansson,C.B., Brismar,H., Shupliakov,O., Frisen,J., Janson,A.M. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc.Natl.Acad.Sci.U.S.A 2003/6/24; 100(-13-):7925-7930. >>> Uridine, bromodeoxy-; thymidine, 3H; Ara-C; Saline, radio-isotopes; CSF/CNS; IP; Mice; 1003D; 1002; 2004; 2,3,10,14,21 days; Comparison of oral administration vs. IP injections; animal info (male, C57BL/6, 2-20 months old); neurodegenerative (Parkinson's disease); "the blood brain barrier and or peripheral metabolism limit the availability of BrdUrd in the brain." (p. 7929).

P8253 Leker,R.R., Soldner,F., Velasco,I., Gavin,D.K., ndroutsellis-Theotokis,A., McKay,R.D.G. Long-lasting regeneration after ischemia in the cerebral cortex. Stroke 2007; 38(-1-):153-161. >>> Ara-C; Saline; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ vehicle; ischemia (cerebral); animal info (SHR, permanent distal middle cerebral artery occlusion).

P8153 Bauer,S., Patterson,P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. Journal of Neuroscience 2006; 26(-46-):12089-12099. >>> Ara-C; leukemia inhibitory factor, recomb. mouse; epidermal growth factor, recomb. human; Saline; PBS; BSA; CSF/CNS; Mice; 1003D; 1007D; 1, 3, 6, 7, days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 or 3 used; peptides; animal info (adult, male, C57BL/6J, 2-6 months old).

P7670 Lim,D.A., Suarez-Farinas,M., Naef,F., Hacker,C.R., Menn,B., Takebayashi,H., Magnasco,M., Patil,N., varez-Buylla,A. In vivo transcriptional profile analysis reveals RNA splicing and chromatin remodeling as prominent processes for adult neurogenesis. MOLECULAR AND CELLULAR NEUROSCIENCE 2006; 31(-1-):131-148. >>> Ara-C; Saline; CSF/CNS; Mice; 1007D; 6 days; Controls received mp w/ vehicle or no treatment; animal info (CD-1, 2-3 months old); anti-mitotic cytosine arabinoside.

P7436 Parras,C.M, Galli,R, Britz,O, Soares,S. Mash 1 specifies neurons and oligodendrocytes in the postnatal brain. The European Molecular Biology Organization Journal 2004; 23(--):4495-4505. >>> Ara-C; Saline; CSF/CNS; Mice; 6 days; Animal info (male, 8-10 weeks old).

P6989 Enwere,E., Shingo,T., Gregg,C., Fujikawa,H., Ohta,S., Weiss,S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. Journal of Neuroscience 2004; 24(-38-):8354-8365. >>> Epidermal growth factor, human recomb.; Ara-C; Saline; albumin, mouse serum; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ vehicle; peptides.

P6701 Rhodes,K.E., Moon,L.D.F., Fawcett,J.W. Inhibiting cell proliferation during formation of the glial scar: Effects on axon regeneration in the CNS. Neuroscience 2003; 120(-1-):41-56. >>> Ara-C; Saline, sterile; CSF/CNS (medial forebrain); CSF/CNS (intrathecal, subarachnoid space); Rat; 1007D; 7 days; Controls received mp w/ vehicle; good methods (P.42); ALZET brain infusion kit used; post op. care (heated recovery box; paracetamol).

P6647 Caille,I., Allinquant,B., Dupont,E., Bouillot,C., Langer,A., Mueller,U., Prochiantz,A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004; 131(-9-):2173-2181. >>> Amyloid precursor protein-Fc, soluble; batimastat; immunoglobulin G, human; amyloid precursor like protein 2-Fc, soluble; oligonucleotide, antisense penetratin; Ara-C; Sodium chloride; saline; CSF/CNS; Mice; 1003D; 1007D; 3,6 days; Controls received mp w/ vehicle; antisense (APP, APLP2); brain tissue distribution; batimastat inhibits clearage of several membrane proteins; neurodegenerative disease (Alzheimer's).

P6400 Zhang,R.L., Zhang,Z.G., Wang,L., Wang,Y., Gousev,A., Zhang,L., Ho,K.L., Morshead,C., Chopp,M. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-4-):441-448. >>> Ara-C; Saline; CSF/CNS (cerebral cortex); Rat; 2001; 7 days; Ischemia (cerebral).

P6362 Maslov,A.Y., Barone,T.A., Plunkett,R.J., Pruitt,S.C. Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice. Journal of Neuroscience 2004; 24(-7-):1726-1733. >>> Ara-C; Saline; CSF/CNS; Mice; 1007D; 7 days; ALZET brain infusion kit.

P5939 Caporaso,G.L., Lim,D.A., Alvarez-Buylla,A., Chao,M.V. Telomerase activity in the subventricular zone of adult mice. MOLECULAR AND CELLULAR NEUROSCIENCE 2003; 23(-4-):693-702. >>> Ara-C; Saline; CSF/CNS (cerebral cortex); Mice; 6 days; Pump model not listed.

P5519 Arvidsson,A., Collin,T., Kirik,D., Kokaia,Z., Lindvall,O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nature Medicine 2002; 8(-9-):963-970. >>> Fibroblast growth factor 2; Epidermal growth factor; Ara-C; CSF, artificial; Albumin, rat serum; CSF/CNS; Rat; 1003D; 12 days; Controls received mp w/ vehicle; Ara-C is also called cytosine beta-D-arabinofuranoside (antimitotic drug); ischemia (cerebral).

P4960 Seri,B., Garcia-Verdugo,J.M., McEwen,B.S., Alvarez-Buylla,A. Astrocytes give rise to new neurons in the adult mammalian hippocampus. Journal of Neuroscience 2001; 21(-18-):7153-7160. >>> Ara-C; Saline; CSF/CNS (surface of brain); mice; 1007D; 7 days; controls received mp w/ vehicle; brain tissue distribution; neurogenesis; AraC is cytosine-Beta-D-arabinofuranoside.

P4404 Gardner,R.V., Astle,C.M., Harrison,D.E. Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy. Experimental Hematology 1997; 25(--):495-501. >>> Ara-C; Mice; 1003D; 3 days; Comparison of IP injections vs. mp; cancer.

P4374 Doetsch,F., Garcia-Verdugo,J.M., Alvarez-Buylla,A. Regeneration of a germinal layer in the adult mammalian brain. Proc.Natl.Acad.Sci.USA 1999/9; 96(--):11619-11624. >>> Ara-C; Saline; CSF/CNS (surface of right hemisphere); Mice; 1007D; 6 days; Ara-C is cytosine-b-D-arabinofuranoside; controls received mp with vehicle.

P4369 Doetsch,F., Caille,I., Lim,D.A., Garcia-Verdugo,J.M., Alvarez-Buylla,A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999/6/11; 97(--):703-716. >>> Thymidine, [3H]-; Ara-C; Radio-isotopes; Saline; 3H Tracer; CSF/CNS; CSF/CNS (surface of brain); mice; 2002; 1007D; 6, 12 days; Ara-C is cytosine-b-D-arabinofuranoside; controls received mp with vehicle.

P2978 Svensson,M., Aldskogius,H. Infusion of cytosine-arabinoside into the cerebrospinal fluid of the rat brain inhibits the microglial cell proliferation after hypoglossal nerve injury. Glia 1993; 7(--):286-298. >>> Ara-C; CSF/CNS (fourth ventricle); CSF/CNS (cisterna magna); rat; 2001; 4,7 days; controls received mp w/ saline; good methods.

P0729 Zaharko,D.S., Covey,J.M. Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice. Invest.New Drugs 1985; 3(--):323-329. >>> Ara-C; DMSO; SC; mice; 2001; 24, 48, 72, 96, and 144 hours; comparison of injection vs. mp infusion; cancer chemotherapy; Lynch coil; polyethylene tubing filled w/Ara-AC connected to mp; mp filled w/ PBS and primed at room temp.; air space in tubing to sep. drug from PBS; function.

P0691 Maurice,D.M., Singh,T. The absence of corneal toxicity with low-level topical anesthesia. Am.J.Ophthalmol. 1985; 93(-6-):691-696. >>> Proparacaine; Eye (corneal stroma); rabbit; 1701; no duration posted; tissue perfusion (central stroma of cornea); comparison of intermittent admin of eye drops vs. mp infusion - analagous to injection/ infusion comparison; mp primed overnight in saline.

P0621 Hoelzer,D., Ganser,A., Schneider,W., Heimpel,H. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes. Semin.Oncol. 1985; 12(-2-):208-211. >>> Ara-C; Saline; IP; mice; 2001; 1 days; cancer chemotherapy; comparison of human and animal data.

top of page

4. Azacytidine

P0604 Zaharko,D.S., Covey,J.M., Kelley,J.A. Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor. Invest.New Drugs 1985; 3(--):35-41. >>> Azacytidine, 5,6-dihydro-5-; PBS; SC; mice; 2001; 4 days; cancer chemotherapy; pumps primed in PBS for 24 hr. prior to implant; solubility limit of DHAC is 820mg/ml at room temp; comparison with previous injec.´ infusion data.

top of page

5. Bleomycin

P9472 Zhou,Y., Koli,K., Hagood,J.S., Miao,M., Mavalli,M., Rifkin,D.B., Murphy-Ullrich,J.E. Latent Transforming Growth Factor-beta-Binding Protein-4 Regulates Transforming Growth Factor-beta 1 Bioavailability for Activation by Fibrogenic Lung Fibroblasts in Response to Bleomycin. American Journal of Pathology 2009; 174(-1-):21-33. >>> Bleomycin; SC; Mice; 2001; 8 days; Controls received mp w/ saline; animal info (female, C57BL/6, Thy-1 -/-, 8-10 wks old); lung fibrosis model.

P9040 Fujimoto,H., Alessandro-Gabazza,C.N., Palanki,M.S.S., Erdman,P.E., Takagi,T., Gabazza,E.C., Bruno,N.E., Yano,Y., Hayashi,T., Tamaki,S., Sumida,Y., Adachi,Y., Suzuki,K., Taguchi,O. Inhibition of nuclear factor-kappa B in T cells suppresses lung fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2007; 176(-12-):1251-1260. >>> Bleomycin; Saline; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; animal info (8-10 wks old, female, C57BL/6, 18-22 g.); bleomycin induced pulmonary fibrosis.

P9036 Azuma,M., Nishioka,Y., Aono,Y., Inayama,M., Makino,H., Kishi,J., Shono,M., Kinoshita,K., Uehara,H., Ogushi,F., Izumi,K., Sone,S. Role of alpha 1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2007; 176(-12-):1243-1250. >>> Bleomycin; Saline; SC; Mice; 2001; ; Controls received mp w/ vehicle; animal info (8 wks old, female, C57BL/6); bleomycin induced pulmonary fibrosis.

P8144 Gu,L., Zhu,Y.J., Yang,X., Guo,Z.J., Xu,W.B., Tian,X.L. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacologica Sinica 2007; 28(-3-):382-391. >>> Bleomycin; Saline; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; functionality of mp verified by examination; no stress (see p.384); animal info (Smad 3 -/- or wt, 8-10 wks old, 17g. 27g.); lung fibrosis model.

P7882 Inayama,M., Nishioka,Y., Azuma,M., Muto,S., Aono,Y., Makino,H., Tani,K., Uehara,H., Izumi,K., Itai,A., Sone,S. A novel I kappa B kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2006; 173(-9-):1016-1022. >>> Bleomycin; SC; Mice; 2001; ; Controls received mp w/ saline; animal info (female, C57BL/6, 8 wk old, 18g.).

P7713 Fujimoto,H., Gabazza,E.C., Taguchi,O., Nishii,Y., Nakahara,H., Bruno,N.E., Alessandro-Gabazza,C.N., Kasper,M., Yano,Y., Nagashima,M., Morser,J., Broze,G.J., Suzuki,K., Adachi,Y. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. American Journal of Pathology 2006; 168(-4-):1086-1096. >>> Bleomycin; Saline; SC; Mice; 7 days; Controls received mp w/ vehicle; animal info (female, C57BL/6, 18-22 g); pulmonary.

P7407 Aono,Y., Nishioka,Y., Inayama,M., Ugai,M., Kishi,J., Uehara,H., Izumi,K., Sone,S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2005; 171(-11-):1279-1285. >>> Bleomycin; Saline; SC; Mice; 2001; 28 days; Controls received mp w/ vehicle; pumps replaced every 7 days; peptides; lung fibrosis induced by bleomycin.

P6658 Haston,C.K., Wang,M., Dejournett,R.E., Zhou,X.H., Ni,D., Gu,X.J., King,T.M., Weil,M.M., Newman,R.A., Amos,C.I., Travis,E.L. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Human Molecular Genetics 2002; 11(-16-):1855-1863. >>> Bleomycin; SC; Mice; ; Minipump usage mentioned on p. 1860; pump model not listed.

P5586 Li,J., Ortiz,L.A., Hoyle,G.W. Lung pathology in platelet-derived growth factor transgenic mice: Effects of genetic background and fibrogenic agents. Experimental Lung Research 2002; 28(-6-):507-522. >>> Bleomycin; SC; mice; 7 days; controls received mp with saline.

P5168 Zhao,J.S., Shi,W., Wang,Y.L., Chen,H., Bringas,P.Jr, Datto,M.B., Frederick,J.P., Wang,X.F., Warburton,D. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 2002; 282(--):L585-L593. >>> Bleomycin sulfate; Saline; SC; Mice (knockout); 1007D; 7 days; Antibiotic; Controls received mp w/ vehicle; functionality verified by residual volume.

P4668 Schwartz,D.R, Homanics,G.E, Hoyt,D.G., Klein,E, Abernethy,J, Lazo,J.S. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance.. Proc.Natl.Acad.Sci. 1999; 96(--):4680-4685. >>> Bleomycin;; Saline;; SC;; rat;; 2001;; 7 days;; Antibiotic; Controls received mp w/ vehicle; cancer; peptides; bleomycin is a glycopeptide anticancer agent;.

P3397 Haston,C.K., Amos,C.I., King,T.M., Travis,E.L. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 1996; 56(--):2596-2601. >>> Bleomycin; Saline; SC; mice; 2001; no duration posted; Antibiotic; controls received mp w/saline; cancer; toxicology.

P2643 Bokemeyer,C., Ludwig,E., Reile,D., Harstrick,A., Poliwoda,H., Schmoll,H.J. Antitumor activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. Oncology Reports 1995; 2(--):161-165. >>> Bleomycin; SC; mice (nude); 7 days; Antibiotic; comparison of bolus ip injections vs. mp; cancer; toxicology; ". . .bolus application of bleomycin is at least as active as continuous infusion. . .".

P2007 Rodgers,K.E., Girgis,W., diZerega,G.S. Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents. Cancer Chemother.Pharmacol. 1992; 29(--):248-251. >>> Doxorubicin HCl; Mitoxantrone; Tolmetin sodium; Bleomycin; Cisplatin; Methotrexate; PBS; IP; rat; 2ML1; 7 days; Antibiotic; cancer; no stress (see p249).

P1707 Kimler,B.F., Martin,D.F., Evans,R.G., Morantz,R.A., Vats,T.S. Combination of radiation therapy and intracranial bleomycin in the 9L rat brain tumor model. Int.J.Radiat.Oncol.Biol.Phys. 1990; 18(--):1115-1121. >>> Bleomycin; CSF/CNS (intratumoral); cattle; rat; 2001; 2002; 7, 14 days; Antibiotic; controls received pumps with saline only; tissue perfusion (tumor); dose-response (graph, p. 1117); comparison of ip injections vs. mp.

P1211 Vanuytsel,L., Feng,Y., Landuyt,W., Begg,A., Van der Schueren,E. Effect of simultaneous administration of bleomycin on the acute skin reactions of mice after single and fractionated doses of radiation. Int.J.Radiat.Oncol.Biol.Phys. 1988; 14(--):103-108. >>> Bleomycin; Saline; SC; mice; 7 days; Antibiotic; Pump model not stated; concomitant radiation treatment; antibiotic.

P1159 Harrison,J.H., Lazo,J.S. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J.Pharmacol.Exp.Ther. 1987; 243(-3-):1185-1194. >>> Bleomycin; Saline; SC; mice; 2001; 1 week; Antibiotic; controls received mp w/ vehicle; C57BL/6, BALB/C mice used; author states mp superior for these experiments; comparison of bolus inject. vs. sc inject. vs. mp infusion; antibiotic.

P1037 Wahlberg,P., Wennerberg,J., Alm,P., Biorklund,A., Trope,C. The effect of continuous bleomycin infusion on the growth and cell kinetics of heterotransplanted squamous cell carcinoma of the head and neck. Anticancer Res. 1987; 7(--):55-58. >>> Bleomycin; Saline; SC; mice; 7 days; Antibiotic; controls received mp with vehicle; half-life data; mice implanted with SCC tumor; cancer therapy; comparison of ip injections vs. mp infusion.

P0493 Osieka,R., Glatte,P., Schmidt,C.-G. Continuous infusion versus intermittent bolus injection of bleomycin in a human embryonal testicular cancer xenograft. Cancer Treat.Rep. 1984; 68(-5-):799-801. >>> Bleomycin; Saline; IP; mice; 2001; 1 week; Antibiotic; comparison of daily intermittent ip injec vs. ip mp infusion; dose-response data; cancer chemotherapy.

P0458 Osieka,V.R. Continuous infusion vs. bolus injection of bleomycin in a human testicular cancer xenograft system. Arzneimittelforschung (German, English summary) 1984; 34(-4-):460-464. >>> Bleomycin; Saline; IP; mice; 2001; 1 week; Antibiotic; cancer therapy; dose range of 10.5-42 mg/kg bleomycin; comparison of daily injec vs. mp infusion; full text is printed in German.

P0383 Kato,T., Mizutani,M., Ota,K. Effect of peplomycin by continuous infusion on Ehrlich carcinoma. Jpn.J.Cancer Chemother. 1983; 10(-3-):763-767. >>> Peplomycin; Bleomycin; IP; mice; 2001; 1 week; Antibiotic; comparison of daily and intermittent injec. vs. mp infusion; cancer chemotherapy.

P0075 Peng,Y.-M., Alberts,D.S., Chen,H.S., Mason,N., Moon,T.E. Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. Br.J.Cancer 1980; 41(-4-):644-647. >>> Bleomycin; Saline; IP; mice; 6 days; Antibiotic; intermittent bolus injection ip vs. infusion; cancer.

P0017 Sikic,B.I., Collins,J.M., Mimnaugh,E.G., Gram,T.E. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat.Rep. 1978; 62(-12-):2011-2017. >>> Bleomycin; Saline; SC; Mice; 7,14 days; Comparison of bolus injections vs. SC minipump; study #1 infused for 7 days and study #2 infused for 14 days; cancer (lung carcinoma); peptides.

top of page

6. CDDP

Q0589 Iwasa,T., Okamoto,I., Takezawa,K., Yamanaka,K., Nakahara,T., Kita,A., Koutoku,H., Sasamata,M., Hatashita,E., Yamada,Y., Kuwata,K., Fukuoka,M., Nakagawa,K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; CDDP; CBDCA; DMSO; IV; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

P6470 Ohtsukasa,S., Okabe,S., Yamashita,H., Iwai,T., Sugihara,K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. Journal of Cancer Research and Clinical Oncology 2003; 129(-12-):719-726. >>> CDDP; fluorouracil, 5-; IP; Mice; 1007D; 14 days; Controls received mp w/ saline; pumps replaced after 7 days; cancer (colorectal); CDDP (Cisdiamminedichloroplatinum II); is a chemotherapeutic agent.

top of page

7. Carboplatin

Q0707 Tange,Y., Miyazaki,M., Iwata,J., Aiko,Y., Sakamoto,S., Mori,K. Novel Antitumor Effect of Carboplatin Delivered by Intracerebral Microinfusion in a Rat Malignant Glioma Model. NEUROLOGIA MEDICO-CHIRURGICA 2009; 49(-12-):572-579. >>> Carboplatin; Glucose, D-; Evans blue; CSF/CNS (intratumoral); Rat; 2001; 3, 7 days; Animal info (male, F344/N Slc, Fischer 220-260 g); brain tissue distribution; ALZET brain infusion kit used; stability verified (4 weeks) pg 573; cancer (glioma); MRI; brain tissue distribution; "... continuous intracerebral microinfusion using the osmotic mini-pump can provide broader distribution of agents than growth of the brain tumor."; "intracerebral microinfusion can attain clinically favorable drug distribution from a single infusion point." pg 576.

Q0589 Iwasa,T., Okamoto,I., Takezawa,K., Yamanaka,K., Nakahara,T., Kita,A., Koutoku,H., Sasamata,M., Hatashita,E., Yamada,Y., Kuwata,K., Fukuoka,M., Nakagawa,K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

P9618 Rousseau,J., Barth,R.F., Moeschberger,M.L., Elleaume,H. EFFICACY OF INTRACEREBRAL DELIVERY OF CARBOPLATIN IN COMBINATION WITH PHOTON IRRADIATION FOR TREATMENT OF F98 GLIOMA-BEARING RATS. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2009; 73(-2-):530-536. >>> Carboplatin; Dextrose; CSF/CNS (intratumoral); Rat; 2001; 6 days; Controls received mp w/vehicle; no stress (see pg. 532); cancer (glioma); ALZET brain infusion kit 2 used; animal info (male, Fisher, 230-260g); "Surgery for pump implantation was well tolerated." pg. 532; "It is noteworthy that the brainstem was not damaged by direct infusion of 200 ul of carboplatin (0.5 mg/mL) at a flow rate of 1uL/h." pg. 535; tissue perfusion (tumor).

P9497 Tange,Y., Kondo,A., Egorin,M.J., Mania-Farnell,B., Daneriallis,G.M., Nakazaki,H., Sredni,S.T., Rajaram,V., Goldman,S., Soares,M.B., Tomita,T. Interstitial continuous infusion therapy in a malignant glioma model in rats. Childs Nervous System 2009; 25(-6-):655-662. >>> Carboplatin; oxaliplatin; Dextrose; IP; CSF/CNS (striatum); Rat; 2001; 5, 7 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; animal info (male, Fischer 344, 180-220 g.); "By taking advantage of continuous infusion as an administration protocol, CED has the potential to be a powerful modality for brain tumor treatment, as prolonged infusion could increase the amount of time a tumor is exposed to a drug." (pg. 656); "The method uses low-volume... continuous infusion and is not expected to increase intracranial pressure." (pg. 656).

P9086 Thomale,U., Tyler,B., Renard,V., Dorfman,B., Guarnieri,M., Haberl,H., Jallo,G. Local chemotherapy in the rat brainstem with multiple catheters: a feasibility study. Childs Nervous System 2009; 25(-1-):21-28. >>> Carboplatin; Dextrose; CSF/CNS (parenchyma); Rat; 2001; 7 days; Controls received mp w/ vehicle; multiple pumps per animal (2, 3); animal info (male, Fisher); polyethylene tubing (PE) used; x-ray of skull showing cannulae position; pg. 22 illustration of pump and implanted cannulae.

P7120 Khan,A., Jallo,G.I, Liu,Y.J, Carson,B.S., Guarnieri,M. Infusion rates and drug distribution in brain tumor models in rats. Journal of Neurosurgery (Pediatrics 1) 2005; 102(--):53-58. >>> Carboplatin; doxorubicin; transferrin-doxorubicin; CSF/CNS; Rat; 2ML1; 2001; 7 days; Cancer (glioma, gliosarcoma); brain tissue distribution; CNS infusion rate study; "...the use of intratumoral infusions significantly increase survival in comparison with bolus injections and conventional systemic treatments." P. 53; flexible tipped cannula components were from Plastics One; in some cases the tubing/cannula were left empty after implantation to allow the tissue to seal before fluid flow.

P5476 Carson,BS Sr, Wu,Q.Z., Tyler,B., Sukay,L., Raychaudhuri,R., Dimeco,F., Clatterbuck,R.E., Olivi,A., Guarnieri,M. New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. Journal of Neuro-oncology 2002; 60(-2-):151-158. >>> Carboplatin; bis-chlorethyl nitrosourea; Propylene glycol; dextrose; CSF/CNS (brain stem); Rat; 2001; 7 days; Controls received mp w/ vehicle; stability verified by HPLC (p. 151); half-life (p. 154) for BCNU is<1 hr; cancer; brain tissue distribution; study evaluated effects of various infusion rates from 1-10 ul/hr to the brainstem and cortex.

top of page

8. Cisplatin

P8870 Chirino,Y.I., Trujillo,J., Sanchez-Gonzalez,D.J., Martinez-Martinez,C.M., Cruz,C., Bobadilla,N.A., Pedraza-Chaverri,J. Selective iNOS inhibition reduces renal damage induced by cisplatin. TOXICOLOGY LETTERS 2008; 176(-1-):48-57. >>> 1400W; cisplatin; Saline; SC; Rat; 2001; 3 days; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); animal info (male, Wistar, 230-275g.).

P8712 Vasvari,G.P., Dyckhoff,G., Kashfi,F., Lemke,B., Lohr,J., Helmke,B.M., Schirrmacher,V., Plinkert,P.K., Beckhove,P., Herold-Mende,C.C. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. International Journal of Cancer 2007; 121(-8-):1697-1704. >>> Cisplatin; IP; Mice (SCID); 1002; 4 weeks; Controls received no treatment; pumps replaced after 2 weeks; no stress (see pg. 1699); cancer (head/neck squamous cell carcinoma); animal info (female, NOD/SCID, 6-8 wks old, 15-25g).

P5734 Berrada,M., Yang,Z., Lehnert,S. Tumor treatment by sustained intratumoral release of 5-fluorouracil: Effects of drug alone and in combined treatments. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2002; 54(-5-):1550-1557. >>> Fluorouracil,5-; cisplatin; PBS; IP; Mice; 1007D; 7 days; Controls received mp w/ PBS; comparison of IP injections vs. mp; cancer; cisplatin also called cis-platinum or cis-DDP.

P5673 Wolters,F.L.C., Klis,S.F.L., de Groot,J.C.M.J., Hamers,F.P.T., Prieskorn,D.A., Miller,J.M., Smoorenburg,G.F. Systemic co-treatment with alpha-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs. Hearing Research 2003; 179(-1-2-):53-61. >>> Cisplatin; Saline; Ear (cochlea); Guinea-pig; 2002; 1 week; Tissue perfusion (cochlea).

P4972 O'Leary,S.J., Klis,S.F.L., de Groot,J.C.M.J., Hamers,F.P.T., Smoorenburg,G.F. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose-dependency of electrophysiological and morphological effects. Hearing Research 2001; 154(--):135-145. >>> Cisplatin; Saline; Ear (cochlea); guinea-pig; 2002; 7 days; tissue perfusion (scala tympani); dose-response (Fig. 1-8); ototoxicity; in-house cochlear cannula used (modified); hearing loss; "the pump model has several advantages: 1) there appears to be less inter-animal variability than via systemic administration; 2) cisplatin dosage can be studied parametrically; 3) the effects of systemic toxicity are avoided" (p. 144).

P4434 Yapp,D.T.T., Lloyd,D.K., Zhu,J., Lehnert,S.M. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice. Anti-cancer Drugs 1998; 9(--):791-796. >>> Cisplatin;; Saline;; IP;; mice;; 1007D;; 4, 8 days; comparison of IP injections vs. mp vs. polymer implants; cancer; Results indicate that cisplatin-polymeric implants are better than mini pumps; however, implants were delivered intratumorally whereas cisplatin delivery via osmotic pump was administered systemically;.

P4169 Arguello,F., Alexander,M.A., Greene Jr,J.F., Stinson,S.F., Jorden,J.L., Smith,E.M., Kalavar,N.T., Alvord,W.G., Klabansky,R.L., Sausville,E.A. Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts. J.Cancer Res.Clin.Oncol. 1998; 124(--):19-26. >>> Cisplatin; Carmustine; Methylellipticinium acetate, 9-chloro-2-; Saline, sterile; SC; IP;; mice; 1003D; 1007D; 3, 7 days; controls received mp w/vehicle; comparison of IV, IP injections vs. mp; cancer; 9-chloro-2-methylellipticinium acetate is a derivative of plant alkaloid ellipticines, a class of topoisomerase II inhibitors.

P3909 Joschko,M.A., Webster,L.K., Bishop,J.F., Yuen,K., Olver,I.N., Narayan,K.N., Ball,D.L. Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft. Cancer Chemother.Pharmacol. 1997; 40(--):534-539. >>> Cisplatin; Saline; SC; mice (nude); 2002; 13 days; comparison of IP injections vs. mp; no stress (see pg. 536); cancer; toxicology.

P3804 Yapp,D.T.T., Lloyd,D.K., Zhu,J., Lehnert,S.M. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int.J.Radiat.Oncol.Biol.Phys. 1998; 42(-2-):413-420. >>> Cisplatin; Saline; IP; mice; 1007D; 7 days; controls received mp w/saline; comparison of intratumoral delivery via implanted biodegradable polymers vs. IP injections vs. mp; no stress (see pg. 415); cancer.

P2525 Moses,B.L., Chan,D.W., Hruban,R.H., Forastiere,A., Richtsmeier,W.J. Comparison of intra-arterial and intravenous infusion of cisplatin for head and neck squamous cell carcinoma in a modified rat model. Arch Otolaryngol.Head Neck Surg. 1993; 119(--):612-617. >>> Cisplatin; IV (saphenous); IA (saphenous); rat (nude); 2ML1; 6 days; tissue perfusion (tumor xenograft); cancer.

P1470 Bouvier,G., Penn,R.D., Kroin,J.S., Beique,R.A., Guerard,M.-J., Lesage,J. Intratumoral chemotherapy with multiple sources. Ann.N.Y.Acad.Sci. 1989; 531(--):212-214. >>> Cisplatin; CSF/CNS (intratumoral); human; 2002; no duration posted; mp connected to multiple microcatheters and cannulae; tissue perfusion (tumor); cancer/immunology.

P0979 Bouvier,G., Penn,R.D., Kroin,J.S., Beique,R., Guerard,M.J. Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 1987; 20(--):286-291. >>> Cisplatin; CSF/CNS (cranium); human; 2002; 10 days; mps connected to cath. bundle with a vinyl sheath; mps maint. in saline bath at 37C; 68 mps used in the subject; intratumoral chemo.; tissue perfusion (brain tumor); cancer.

P0778 Morrison,P.F., Dedrick,R.L. Transport of cisplatin in rat brain following microinfusion: an analysis. J.Pharm.Sci. 1986; 75(-2-):120-128. >>> Cisplatin; HCl; Mannitol; Saline; CSF/CNS (cerebellum); rat; 2001; 160 hours.

P0422 Akaza,H., Murphy,W.M., Soloway,M.S. Bladder cancer induced by noncarcinogenic substances. J.Urol. 1984; 131(--):153-155. >>> Formalin, neutral buffered; Water; Cisplatin; Mitomycin C; Saline; Saline; bladder; rat; 2002; 1, 2, and 3 weeks; cancer; comparison of agents carcinogenic effects; empty mp used in one exp.; mp connected to catheter in bladder; confusion over length of pumping time-states 18-22 days for 14 day pump; tissue perfusion.

P0406 Penn,R.D., Kroin,J.S., Harris,J.E., Chiu,K.M., Braun,D.P. Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. Appl.Neurophysiol. 1983; 46(--):240-244. >>> Fluorouracil; Cisplatin; Saline; CSF/CNS (cerebellum); rat; 2001; 1 week; comparison of agents effects; tissue perfusion (intratumoral); cancer chemotherapy.

P0217 Kroin,J.S., Penn,R.D. Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 1982; 10(-3-):349-354. >>> Cisplatin; HCl; Mannitol; Saline; CSF/CNS (cerebellum); CSF/CNS (frontal cortex); rat; 2001; 5-7 days; comparison of iv inject. vs. mp infusion; intracerebral cancer chemotherapy in normal rats; no stress (see pg. 352-3).

top of page

9. Cyclophosphamide

P9990 Mercapide,J., Rappa,G., Anzanello,F., King,J., Fodstad,O., Lorico,A. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. International Journal of Cancer 2010; 126(-5-):1206-1215. >>> Cyclophosphamide; CSF/CNS; Mice (nude); ; Controls received mp w/ sterile saline; animal info (6 wks old, female).

P7768 Damber,J.E., Vallbo,C., Albertsson,P., Lennernaes,B., Norrby,K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemotherapy and Pharmacology 2006; 58(-3-):354-360. >>> Cyclophosphamide; paclitaxel; Saline; SC; Rat; 2ML1; 10 days; Controls received mp w/ vehicle; cancer (AT-1 adenocarcinoma); animal info (adult, male, copenhagen); "Continuous/metronomic therapy may achieve a more pronounced anti-tumoural effect and significantly diminish the side effects compared with conventional bolus MTD-type chemotherapy." (p. 359).

P4591 Reiners,W, Wittfoht,H, Nau,R, Vogel,R, Tenschert,B, Spielmann,H. Teratogenesis and pharmacokinetics of cyclophosphamide after drug infusion as compared to injection in the mouse during day 10 of gestation.. Pharmacokinetics in Teratogenesis 1987; II(-Chap. 4-):41-48. >>> Cyclophosphamide; NaCl; PEG 300;; SC;; mice;; 2001;; 24 hours;; functionality of mp verified by plasma levels; comparison of bolus injections vs. mp; half-life (p. 42);.

P1969 Tagliabue,G., Filippeschi,S., Hendricks,H., D'Incalci,M. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (dabis maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX. Ann.Oncol. 1992; 3(--):233-236. >>> Dabis maleate; Cyclophosphamide; Water; SC; mice; 3 days; cancer.

P1723 Zaharko,D.S. Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivo. J.Immunopharmacol. 1985; 7(-2-):195-202. >>> Cyclophosphamide; Cytidine, 5-aza-2'-deoxy-; SC; mice; 2001; 12 hours; comparison of ip injections vs. mp; immunology.

top of page

10. Doxorubicin

P9568 Loch,T., Vakhrusheva,O., Piotrowska,I., Ziolkowski,W., Ebelt,H., Braun,T., Bober,E. Different extent of cardiac malfunction and resistance to oxidative stress in heterozygous and homozygous manganese-dependent superoxide dismutase-mutant mice. Cardiovascular Research 2009; 82(-3-):448-457. >>> Doxorubicin; PBS; SC; Mice; 2002; 2 weeks; Controls received mp w/vehicle; animal info (4.5 mo. old).

P8944 Wenzel,P., Mueller,J., Zurmeyer,S., Schuhmacher,S., Schulz,E., Oelze,M., Pautz,A., Kawamoto,T., Wojnowski,L., Kleinert,H., Muenzel,T., Daiber,A. ALDH-2 deficiency increases cardiovascular oxidative stress - Evidence for indirect antioxidative properties. Biochemical and Biophysical Research Communications 2008; 367(-1-):137-143. >>> Nitroglycerin; acetaldehyde; doxorubicin; Ethanol; SC; IP; Mice; 3, 4 days; Controls received mp w/ vehicle; cardiovascular; animal info (10 wks old, male, ALDH-2 null); nitroglycerin also known as glycerol trinitrate, GTN; "chronic (in contrast to short term/acute) treatment with doxorubicin lead to a more pronounced increase in mitochondrial ROS formation and to a greater extent of endothelial as well as smooth muscle dysfunction" pg. 141.

P7394 Guarnieri,M., Carson,B.S., Khan,A., Penno,M., Jallo,G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. Journal of Neuroscience Methods 2005; 144(-2-):147-152. >>> Doxorubicin; carboblatin; Dextrose solution; saline; CSF/CNS (parenchyma); Rat; 2001; ; Animal info (F, Fischer, 220 g); Functionality of mp verified by pump examination, post infusion; stability verified by previous studies, 14 days; good methods (p. 148); cancer (glioma); brain tissue distribution; Plastics One cannula used (stainless steel); "replacement of rigid infusion tubes [cannulae] with flexible tubing increases the reliability of local CNS drug infusions. Rigid catheters [cannulae] may allow backflow of the infused drug along the path of the catheters into the subdural space." (P. 147).

P6033 Boengler,K., Pipp,F., Fernandez,B., Ziegelhoeffer,T., Schaper,W., Deindl,E. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovascular Research 2003; 59(-3-):573-581. >>> Monocyte chemoattractant protein-1; doxorubicin; transforming growth factor-B1; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular.

P5729 Boengler,K., Pipp,F., Fernandez,B., Richter,A., Schaper,W., Deindl,E. The ankyrin repeat containing SOCS box protein 5: a novel protein associated with arteriogenesis. Biochemical and Biophysical Research Communications 2003; 302(-1-):17-22. >>> Monocyte chemoattractant protein-1; Transforming Growth Factor-B; Doxorubicin; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular; peptides; MCP-1 is monocyte chemoattractant protein 1.

P2788 Naito,K., Kanbayashi,N., Nakajima,S., Murai,T., Arakawa,K., Nishimura,S., Okuyama,A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int.J.Cancer 1994; 58(--):730-735. >>> BE16627B; Doxorubicin HCl; DMSO; Ethylene glycol; SC; mice (nude); 2001; 2002; 3 weeks, 18 days; controls received vehicle or no treatment; pumps replaced; stress/ adverse reaction: skin inflammation and necrosis around delivery site in mice treated with Adriamycin (pg. 733); BE166278B animals were fine; stability verified for 18 days by assay; cancer; enzyme inhibitor; BE16627B is a metalloproteinase inhibitor; 2002 replaced w/ 2001 after 20 days; adriamycin is doxorubicin HCl.

P2389 Slate,D.L., Fraser-Smith,E.B., Rosete,J.D., Freitas,V.R., Kim,Y.N., Casey,S.M. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps. Invivo 1993; 7(--):519-524. >>> Doxorubicin; Verapamil; PBS; IP; mice; 2001; 7 days; functionality of mp verified by plasma levels; dose-response (table, p. 520); comparison of i.p. injections vs. mp; cancer; authors used ALZET pumps to "..mimic prolonged i.v. coadministration in the clinic and to compare the efficacy and toxicity of this delivery scheme with more traditional bolus i.p. regimens.".

top of page

11. Endostatin

P8793 Kurosaka,D., Yoshida,K., Yasuda,J., Yasuda,C., Noda,K., Furuya,K., Ukichi,T., Kingetsu,I., Joh,K., Yamaguchi,N., Saito,S., Yamada,A. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2007; 36(-6-):434-441. >>> Endostatin; PBS; IP; Mice; 2 weeks; Controls received mp w/ vehicle; animal info (1J, 6 week); "compared with the once daily dosing regimen, the administration of endostatin by an osmotic pump achieved a similar arthritis-inhibiting effect at one-tenth of the dose...the administration method using osmotic pump is useful." pg. 434.

P8357 Mulder,W.J.M., van der Schaft,D.W.J., Hautvast,P.A.I., Strijkers,G.J., Koning,G.A., Storm,G., Mayo,K.H., Griffioen,A.W., Nicolay,K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal 2007; 21(-2-):378-383. >>> Endostatin; anginex; SC; Mice; 2 weeks; 3 days; Controls received mp w/ saline; cancer (melanoma); peptides; MRI; animal info (C57BL/6, 6 weeks old); antiangiogenesis.

P8275 Tanabe,K., Maeshima,Y., Ichinose,K., Kitayama,H., Takazawa,Y., Hirokoshi,K., Kinomura,M., Sugiyama,H., Makino,H. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney International 2007; 71(-3-):227-238. >>> Endostatin (1-27), human; PBS; SC; Mice; 2004; 24 days; Controls received mp w/ vehicle; dose-response (fig. 1); no stress (see pg. 234); animal info (male, ICR, female, 6 weeks old, 27 grams, peritoneal sclerosis); "Continuous administration of endostatin peptide via subcutaneous osmotic minipumps did not produce any harmful side effects...In addition, treatment with endostatin peptide did not give rise to any pathological alterations in the heart, liver, or kidney, and failed to affect wound repair" (p. 234); nephrology.

P7564 Ichinose,K., Maeshima,Y., Yamamoto,Y., Kitayama,H., Takazawa,Y., Hirokoshi,K., Sugiyama,H., Yamasaki,Y., Eguchi,K., Makino,H. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005; 54(-10-):2891-2903. >>> Endostatin, human (1-27); PBS; SC; Mice; 2004; 2 weeks; Controls received mp w/ vehicle; replacement therapy (STZ diabetes); dose-response (fig. 2); no stress (see pg.2892); peptides; animal info (female, C57BL/6, 21-26 g).

P7040 Moulton,K.S., Olsen,B.R., Sonn,S., Fukai,N., Zurakowski,D., Zeng,X.K. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004; 110(-10-):1330-1336. >>> Endostatin, murine; SC; Mice; 5 days; Functionality of mp verified by serum endostatin levels; dose-response (fig. 6); cardiovascular.

P6791 Olsson,A.K., Johansson,I., Aakerud,H., Einarsson,B., Christofferson,R., Sasaki,T., Timpl,R., Claesson-Welsh,L. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Research 2004; 64(-24-):9012-9017. >>> Endostatin (180-199), human; endostatin (180-199/mut), human; IP; Mice (SCID); 1007D; 3 weeks; Controls received mp w/ endostatin (180-199/mut); comparison of SC injections vs. mp; pumps replaced every week; cancer (pancreatic carcinoma); peptides; "Continuous delivery of endostatin w/ mini osmotic pumps implanted intraperitoneally in mice has been shown to be more efficient and to require a lower dose to achieve the same antitumor effect." (p. 9015).

P6556 Nap,A.W., Griffioen,A.W., Dunselman,G.A.J., Bouma-Ter Steege,J.C.A., Thijssen,V.L.J.L., Evers,J.L.H., Groothuis,P.G. Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology and Metabolism 2004; 89(-3-):1089-1095. >>> Endostatin; anginex; SC; Mice (nude); 1002; 2 weeks; Controls received SC saline daily; no stress (see pg.1092); peptides; "The angiostatic agents did not appear to affect the overall health of the mice...The behavior of the mice during treatments was normal as well." (p. 1092).

P6262 Yu,Y., Moulton,K.S., Khan,M.K., Vineberg,S., Boye,E., Davis,V.M., O'Donnell,P.E., Bischoff,J., Milstone,D.S. E-selectin is required for the antiangiogenic activity of endostatin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-21-):8005-8010. >>> Endostatin; IP; 2001; 5 days.

P6187 Abraham,D., Abri,S., Hofmann,M., Hoeltl,W., Aharinejad,S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. Journal of Urology 2003; 170(-4-):1388-1393. >>> Thrombospondin-1; endostatin, recomb. mouse; Ringer's solution; SC; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; cancer (testicular); thrombospondin-1 is also known as tsp-1.

P6133 Capillo,M., Mancuso,P., Gobbi,A., Monestiroli,S., Pruneri,G., Dell'Agnola,C., Martinelli,G., Shultz,L., Bertolini,F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clinical Cancer Research 2003; 9(-1-):377-382. >>> Endostatin, recomb. human; PBS; SC; Mice (SCID); 2001; 2002; 1,2 weeks; Controls received mp w/ vehicle; comparison of bolus IP or SC injections vs. mp; cancer (lymphoma).

P5997 Kuroiwa,M., Takeuchi,T., Lee,J.H., Yoshizawa,J., Hirato,J., Kaneko,S., Choi,S.H., Suzuki,N., Ikeda,H., Tsuchida,Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. Journal of Pediatric Surgery 2003; 38(-10-):1499-1505. >>> Endostatin, recomb. human; Saline; SC; Mice (nude); 1003D; 3 days; Controls received 3 mp w/ vehicle; comparison of SC injections vs. mp; no stress (see p. 1501); cancer (neuroblastoma); angiogenesis inhibitor; multiple pumps per animal (3); picture of nude mouse w/3 pumps (fig.1; p. 1500); "The set of 3 osmotic pumps was retained successfully in the subcutaneous tissue of the treated and control animals throughout the experiment, no decrease in body weight was observed in either group." (p. 1501).

P5950 Schmidt,N.O., Ziu,M., Carrabba,G., Giussani,C., Bello,L., Sun,Y.P., Schmidt,K., Albert,M., Black,P.M., Carroll,R.S. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clinical Cancer Research 2004; 10(-4-):1255-1262. >>> Endostatin, recomb. murine; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 21 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; comparison of SC injections vs. chronic ICV mp; no stress (see pg. 1261); cancer (glioma); ALZET brain infusion kit 1 used (per Dr. Carroll); MRI; "The direct infusion of therapeutic compounds into brain tumors can overcome some of the obstacles of drug delivery." p. 1255; BIK's removed prior to MRI; "no signs of intracranial bleeding due to the presence of the pumps or antiangiogenic treatment were observed..." (p. 1261); angiogenesis inhibitor; surgical glue used to affix cannula to the skull.

P5820 Sorensen,D.R., Leirdal,M., Iversen,P.O., Sioud,M. Combination of endostatin and a protein kinase C alpha DNA enzyme improves the survival of rats with malignant glioma. NEOPLASIA 2002; 4(-6-):474-479. >>> Endostatin, LPS; PI-88; IP; mice; 2004; 28 days; cancer; recombinant human endostatin used; PI-88 is an anticoagulant mannopentaose phosphate sulfate; angiogenesis inhibitors. Agents given singly or concomitantly in same pump.

P5030 Kisker,O., Becker,C.M., Prox,D., Fannon,M., D'Amato,R., Flynn,E., Fogler,W.E., Sim,B.K., Allred,E.N., Pirie-Shepherd,S.R., Folkman,J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001/10/15; 61(-20-):7669-7674. >>> Endostatin; Sodium citrate; Sodium phosphate; IP; mice (SCID); mice; 2001; 14, 24, 32 days; controls received mp w/ vehicle; functionality of mp verified by serum endostatin levels; dose-response (p.7673, Fig. 4); comparison of SC and IP bolus injections vs. continuous infusion w/ mp; pumps replaced every 7 days; endostatin stability verified by in vitro biologic activity after 1-7 day implantation; half-life (p. 7669) of endostation in mice after SC bolus is ~10 hrs.; cancer; angiogenesis inhibitor; recomb. human endostatin used; continuous administration of human endostatin resulted in increased efficacy and an 8-10-fold decrease in dose required to achieve the same effect as daily bolus administration.

top of page

12. Etoposide

P9777 Giraud,S., Bessette,B., Boda,C., Lalloue,F., Petit,D., Mathonnet,M., Jauberteau,M.O. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(--):273-281. >>> Fas ligand; etoposide; dexamethasone; CSF, artificial; CSF/CNS (intratumoral); Rat (nude); 1002; 15 days; Tissue perfusion (tumor); functionality of mp verified by residual volume; cancer (glioblastoma); animal info (female 2 months old, 159 g.).

P5213 Peng,D., Qian,C., Sun,Y., Barajas,M.A., Prieto,J. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol. 2000/6; 32(-6-):975-985. >>> Etoposide; IP; Rat; 1 week; Functionality of mp verified by measuring etoposide concentration in tumor tissue; cancer; etoposide (VP-16) is a chemotherapeutic agent.

P2546 de Haan,G., Engel,C., Dontje,B., Loeffler,M., Nijhof,W. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. Cancer Res. 1995; 55(--):324-329. >>> Erythropoietin; Colony-stimulating factor, G; Etoposide; SC; mice; 7 days; dose-response curves (pg. 326-328); cancer; peptides; etoposide is VP-16-213; EPO and VP-16-213 given in same pump initially, but this inactived the G-CSF; multiple pumps per animal (1-2) for G-CSF/VP-16 mice.

P2305 Claessen,A.M.E., Bloemena,E., Bril,H., Meijer,C.J.L.M., Scheper,R.J. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res. 1992; 52(--):2440-2446. >>> Interleukin-2; Etoposide; SC; guinea-pig; 2001; 2002; 1 and 2 weeks; comparison of local injections vs. mp (table, p. 2442); cancer.

P1471 Claessen,A.M., Valster,H., Bril,H., Meyer,S., Scheper,R.J. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol.Immunother. 1989; 28(--):131-135. >>> Etoposide; Fluorouracil, 5-; SC; guinea-pig; 2001; 7 days; comparison of sc injections vs. mp infusion; cancer/immunology; VP-16-213 is etoposide.

top of page

13. Fluorouracil

Q0930 Rasi,G., Silecchia,G., Sinibaldi-Vallebona,P., Spaziani,E. ANTI-TUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA 1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL CANCER IN RATS. Int.J.Cancer 1994; 55(--):701-705. >>> Fluorouracil, 5-; Saline, heparinized; IP; Rat; 2ML2; 7 days; Animal info (male, inbred, BDIX, 8 wks old, 220-250 g); functionality of mp verified; cancer (liver metastases); no stress (see pg. 702) "The continuous systemic infusion of 5-FU... did not show any significant side effects".

Q0929 Silecchia,G., Guarino,E., Sinibaldi-Vallebona,P., Pierimarchi,P., Restuccia,A., Spaziani,E., Bernard,P., Tuthill,C., Garaci,E., Rasi,G. Efficacy of repeated cycles of chemo-immunotherapy with Thymosin alpha 1 and interleukin-2 after intraperitoneal 5-uorouracil delivery. Cancer Immunol.Immunother. 1998; 48(--):172-178. >>> Fluorouracil, 5-; Saline, heparinized; IP; Rat; 2ML1; 7 days; Controls received mp w/ vehicle; animal info (male, BDIX, inbred, 220-250 g, 8 wks old); functionality of mp verified; polyethylene IP catheter used.

Q0812 Tsukioka,S., Uchida,J., Tsujimoto,H., Nakagawa,F., Sugimoto,Y., Oka,T., Kiniwa,M. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice. Molecular Medicine Reports 2009; 2(-3-):393-398. >>> Fluorouracil, 5-; Sailne, sterile; SC; Mice; 2002; 14 days; Animal info (BALB/cA-nu/nu, 4-5 wks old); cancer (colorectal); "oral S-1/LV therapy inhibited the growth of COL-1 tumors more effectively than the infusion of 5-FU/LV when administered at doses of similar toxicity" pg 397.

P9489 Albertsson,P., Lennernaes,B., Norrby,K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncologica 2009; 48(-3-):418-425. >>> Fluorouracil, 5-; NaCl; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; no stress (see pg. 420); pumps primed; "No animal died during the surgical procedure or post surgical period"; angiogenesis; "The animals behaved normally and there were no signs of diarrhea or stomatitis." pg 240.

P8790 Terazono,H., Hamdan,A., Matsunaga,N., Hayasaka,N., Kaji,H., Egawa,T., Makino,K., Shigeyoshi,Y., Koyanagi,S., Ohdo,S. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: A possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochemical Pharmacology 2008; 75(-8-):1616-1622. >>> Fluorouracil, 5-; SC; Mice; 2001; 7 days; Controls received mp w/ saline; animal info (male, ICR, 7 wks old).

P7931 Yurimoto,S., Miyakawa,A., Okuzawa,A., Sakamoto,S., Sakamoto,K., Hosoda,S., Kamano,T. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. Anti-cancer Drugs 2005; 16(-10-):1109-1114. >>> Fluorouracil, 5-; IP; Mice; 1007D; 8 days; Cancer (sarcoma-180); animal info (six week old, male, 30 grams); tumor cells in abdomen; chemotherapeutic.

P7764 Pukac,L., Kanakaraj,P., Humphreys,R., Alderson,R., Bloom,M., Sung,C., Riccobene,T., Johnson,R., Fiscella,M., Mahoney,A., Carrell,J., Boyd,E., Yao,X.T., Zhang,L., Zhong,L., von Kerczek,A., Shepard,L., Vaughan,T., Edwards,B., Dobson,C., Salcedo,T., Albert,V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer 2005; 92(-8-):1430-1441. >>> Fluorouracil, 5-; SC; Mice (nude); 2002; 14 days; Controls received no treatment; cancer (colon); animal info (female, Swiss, athymic, 7-8 wk old, 20g.).

P7697 Stoeltzing,O., Liu,W., Reinmuth,N., Fan,F., Parry,G.C., Parikh,A.A., McCarty,M.F., Bucana,C.D., Mazar,A.P., Ellis,L.M. Inhibition of integrin alpha beta 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int.J.Cancer 2003/4/20; 104(-4-):496-503. >>> Fluorouracil, 5-; Saline; IP; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cancer; angiogenesis; "In preliminary studies..., we observed severe side effects with 5-FU...biweekly injections...thus, we chose to deliver 5-FU by continuous infusion...to minimize toxicity. Additionally, studies have demonstrated an increased efficacy of chemotherapeutic agents when administered continuously." (p. 497).

P7261 Nakano,K., Todo,T., Zhao,G., Yamaguchi,K., Kuroki,S., Cohen,J.B., Glorioso,J.C., Tanaka,M. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. JOURNAL OF GENE MEDICINE 2005; 7(-5-):638-648. >>> Fluorouracil, 5-; IP; Mice (SCID); hamster; 2 weeks; Cancer (gastric, gall bladder carcinoma); pyrimidine synthesis inhibitor.

P6394 Sudoh,M., Kishimoto,Y., Marumoto,B., Inoue,M., Sano,A., Miura,N., Horie,Y., Hasegawa,J., Ryoke,K. A new animal model of continuous catheterization for investigating mechanisms of arteritis associated with chemotherapy. LIFE SCIENCES 2004; 74(-24-):3025-3032. >>> Fluorouracil, 5-FU; peplomycin; Saline, heparinized; IA (abdominal aorta); Rat; 2ML1; 7 days; Controls received mp w/ vehicle; cancer; chemotherapeutic agents; PE-10 and 60 used; tubing attached using a moment binding agent (alon-alfa); catheter schematic p. 3027; pump placed IP.

P6216 Suzuki,Y., Ishibiki,Y., Kawai,K., Sasaki,M., Matsuda,M., Watanabe,T., Shirasaka,T., Kamano,T. Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma. Anti-cancer Drugs 2003; 14(-6-):475-479. >>> Fluorouracil, 5-; IP; Mice; 1007D; 5 days; Controls received no treatment; cancer (sarcoma); transplantation.

P6215 Desmoulin,F., Gilard,V., Malet-Martino,M., Martino,R., Molina,C., Smith,P. Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats, in tumour models and in patients. Xenobiotica 2003; 33(-3-):289-303. >>> Fluorouracil, 5-; Rat; 20 days; Cancer (sarcoma); pump model not listed.

P4634 Shirasaka,T, Shimamoto,Y, Ohshimo,H, Saito,H, Fukushima,M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.. Cancer Chemother.Pharmacol. 1993; 32(--):167-172. >>> Fluorouracil, 5-;; Saline;; IV;; rat;; 6 days;; controls received saline infusion; cancer; does not specify the use of ALZET pumps; FUra was continuously infused..

P4070 Iwasaki,Y., Kitamura,M., Arai,K. Intrahepatic arterial infusion chemotherapy with angiotensin II for liver metastasis from gastric cancer. Jpn.J.Cancer Chemother. 1998; 25(-9-):1412-1415. >>> Angiotensin II; Fluorouracil, 5-; Saline; IV; 5 days; article written in Japanese with English summary; cancer; peptides.

P1169 Weinberg,M.J., Rauth,A.M. 5-fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int.J.Radiat.Oncol.Biol.Phys. 1987; 13(-11-):169-. >>> Fluorouracil, 5-; Saline; SC; mice; 2001; 4, 7, 14 days; varying doses of agent infused; seperate and simultaneous radiation therapy; mps used for 7 and 14 days were left in for the duration of the exp.; comparison of ip bolus injections vs. mp infusion; cancer.

P0947 Weinberg,M.J., LaPointe,T.A., Rauth,A.M. Growth delay in a murine squamous cell tumor after local radiation and concurrent infusional 5-fluorouracil treatment. Int.J.Radiat.Oncol.Biol.Phys. 1986; 12(--):1449-1452. >>> Fluorouracil, 5-; SC; mice; 7 days; 4 doses of 5FU infused; agent infused in comb. w/radiation; cancer (squamous cell tumors).

top of page

14. Marimastat

P9727 Skipper,J.B., McNally,L.R., Rosenthal,E.L., Wang,W.Q., Buchsbaum,D.J. In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES 2009; 71(-1-):1-5. >>> Marimastat; DMSO; SC; Mice (nude); 2002; 14 days; Controls received mp w/vehicle; cancer; animal info (3 mo old, female).

P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor; half-life (pg 1894) "<2h in the mouse" 6.1h in larger animals.

P5943 Wada,N., Otani,Y., Kubota,T., Kimata,M., Minagawa,A., Yoshimizu,N., Kameyama,K., Saikawa,Y., Yoshida,M., Furukawa,T., Fujii,M., Kumai,K., Okada,Y., Kitajima,M. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. CLINICAL&EXPERIMENTAL METASTASIS 2003; 20(-5-):431-435. >>> Marimastat; DMSO; water; SC; Mice (SCID); 2002; 2 weeks; controls received mp w/ vehicle; enzyme inhibitor (matrix metalloprotease); marimastat, the broad-spectrum matrix metalloproteinase inhibitor was dissolved in 50% DMSO; angiogenesis inhibitor.

P5454 Charoenrat,P., Rhys-Evans,P., Eccles,S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. International Journal of Cancer 2002; 100(-5-):527-533. >>> Marimastat; DMSO; Water, sterile; SC; Mice; 2002; 17 days; Controls received mp w/ vehicle; cancer; enzyme inhibitor (matrix metalloproteinase).

P5338 Kimata,M., Otani,Y., Kubota,T., Igarashi,N., Yokoyama,T., Wada,N., Yoshimizu,N., Fujii,M., Kameyama,K., Okada,Y., Kumai,K., Kitajima,M. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Japanese Journal of Cancer Research 2002; 93(-7-):834-841. >>> Marimastat; DMSO; SC; Mice (nude); 28 days; Controls received mp w/ vehicle; pumps replaced after 14 days; gastric cancer; enzyme inhibitor; matrix metalloproteinase inhibitor; 50% DMSO vehicle.

top of page

15. Methotrexate

P9442 Scholz,J., Abele,A., Marian,C., Haeussler,A., Herbert,T.A., Woolf,C.J., Tegeder,I. Low-dose methotrexate reduces peripheral nerve injury-evoked spinal microglial activation and neuropathic pain behavior in rats. Pain 2008; 138(-1-):130-142. >>> Methotrexate; dexamethasone; CSF, artificial; PBS; CSF/CNS (intrathecal); Rat; 7, 14 days; Controls received mp w/ vehicle; dose-response (fig. 7); comparison of IP injections vs. mp; enzyme inhibitor (dihydrofolate reductase); animal info (male, Sprague Dawley, 160-200 g., SNI); behavioral testing (paw withdrawal, mechanical allodynia, cold allodynia); "sustained intrathecal treatment may therefore suppress microglial activation much more efficiently than intermittent high-dose bolus injections." (p. 140).

P7278 Lobo,E.D., Balthasar,J.P. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. Journal of Pharmaceutical Sciences 2005; 94(-9-):1957-1964. >>> Methotrexate; IP; Mice; 1003D; 72 hours; Controls received ip bolus saline injection; dose-response (fig. 3); cancer (peritoneal sarcoma); toxicology; mp primed overnight in 37 degrees saline.

P6106 Lobo,E.D., Soda,D.M., Balthasar,J.P. Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti--methotrexate antibodies in mice. Journal of Pharmaceutical Sciences 2003; 92(-8-):1665-1676. >>> Methotrexate; Saline; IP; Mice; ; Controls received mp w/ vehicle; IP catheters used; pump model or duration not stated.

P6105 Lobo,E.D., Balthasar,J.P. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. Journal of Pharmaceutical Sciences 2003; 92(-8-):1654-1664. >>> Methotrexate; Saline; IP; Mice; 1003D; 2001D; 2001; 1,3,7 days; Controls received mp w/ vehicle; mtx plasma levels taken; dose-response (p. 1659); comparison of bolus injections vs. IP mp; toxicology; IP catheter used.

P2622 Abraham,A., Nair,M.G., McGuire,J.J., Galivan,J., Kisliuk,R.L., Vishnuvajjala,B.R. Antitumor efficacy of classical non-polyglutamylatable antifolates that inhibit dihydrofolate reductase. In 'Chemistry and Biology of Pteridines and Folates,' J.E.Ayling (ed.), Plenum Press, New York 1993; (--):663-666. >>> MEDAM; Methotrexate; SC; mice; no duration posted; comparison of injections, oral administration and pellets vs. mp; cancer; toxicology; MEDAM is gamma-methylene-10-ethyl-10-deazaaminopterin.

P2468 Pinski,J., Schally,A.V., Yano,T., Szepeshazi,K., Halmos,G., Groot,K., Comaru-Schally,A.M., Rakulovic,S., Nagy,A. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. The Prostate 1993; 23(--):165-178. >>> Luteinizing HRH; Methotrexate; AJ-004; G-HMAQ; T-98; Propylene glycol; Water; SC; rat; 2ML4; 7-8 weeks; controls received tumors and mp w/ vehicle; long-term study, pumps replaced after 4 weeks; cancer (prostate); toxicology; peptides; T-98 and AJ-004 are hybrid cytoxic LH-RH analogs; D-Lys6-LHRH used.

P1616 Shibutani,M., Okeda,R. Experimental study on subacute neurotoxicity of methotrexate in cats. Acta Neuropathol.(Berl) 1989; 78(--):291-300. >>> Methotrexate; Saline; CSF/CNS; cat; 2ML4; 5-28 days; comparison of intracisternal injections vs. mp.

P1347 Taylor,E., Geyer,R., Milstein,J., Shaw,C., Geraci,J., Wootton,P., Hubbard,B., Bleyer,W. Rodent models of chemoradiotherapy-induced white matter necrosis. Natl.Cancer Inst.Monogr. 1988; 6(--):59-64. >>> Methotrexate; Saline; CSF/CNS; rat; 2002; 14 days; mp connected to cannula; dose-response (text); functionality of mp verified by plasma levels; cancer.

P0592 Sendelbeck,S.L., Urquhart,J. Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Research 1985; 328(--):251-258. >>> Antipyrine; Dopamine HCl; Methotrexate, sodium; Radio-isotopes; 14C tracer; 3H tracer; CSF, artificial; Sodium fluorescein; CSF/CNS (diencephalon); rabbit; 2001; 6 days; comparison of agents effects; mp primed in saline 16 hr. prior to implant; stability of labelled&unlabelled Dop.&MTX tested by paper chromat. after 7 days at 37C; brain tissue distribution;.

P0005 Pinedo,H.M., Zaharko,D.S., Bull,J., Chabner,B.A. The relative contribution and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res. 1977; 37(--):445-450. >>> Methotrexate; SC; Mice; 12, 24, 48, 72 hours; Functionality of mp verified by methotrexate plasma levels and in vitro release.

P0002 Pinedo,H.M., Chabner,B.A., Zaharko,D.S., Bull,J.M. Evidence for early recruitment of granulocyte precursors during high-dose methotrexate infusions in mice. Blood 1976; 48(-2-):301-307. >>> Methotrexate; SC; mice; 12, 24, or 48 hours; methotrexate plasma levels.

top of page

16. Mitomycin

P1993 Fu,K.K., Lam,K.N. Early and late effects of mitomycin C and continuous low-dose-rate irradiation on the mouse skin and soft tissues of the leg. Int.J.Radiat.Oncol.Biol.Phys. 1991; 21(--):1523-1528. >>> Mitomycin C; Saline; IP; mice; no duration posted; cancer.

P1874 Lu,X., Richardson,P.M. Inflammation near the nerve cell body enhances axonal regeneration. J.Neurosci. 1991; 11(-4-):972-978. >>> Mitomycin C; CSF/CNS (spinal cord, intrathecal); rat; no duration posted; no comment posted.

P1302 Kawano,S., Yano,S., Sakamoto,S., Ogata,J. Effect of continuous intravesical infusion of low-concentrated mitomycin-C on bladder carcinogenesis in rats treated with N-butyl-N-4-hydroxybutyl-nitrosamine. J.Urol. 1988; 139(--):1343-1346. >>> Mitomycin C; bladder; rat; 2ML2; 2 weeks; mp connected to catheter; dose-response (graph, text); comparison of twice weekly injections vs. mp infusion; functionality of mp verified by urine levels; cancer/immunology; tissue perfusion.

P0818 Murphy,W.M., Blatnik,A.F., Shelton,T.B., Soloway,M.S. Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters. J.Urol. 1986; 135(-4-):840-844. >>> Mitomycin; Water; bladder; rat; 1 year and 3 weeks; pump replaced periodically; mp connected to bladder via catheter; tumors induced by infusion of water or agent; lesions reversible over time; long-term study; cancer; controls received surgery only; mps cultured upon removal; tissue perfusion.

top of page

17. Other Chemotherapeutics

Q0773 Cuevas,P., Carceller,F., Angulo,J., Gonzalez-Corrochano,R., Cuevas-Bourdier,A., Gimenez-Gallego,G. Antiglioma effects of a new, low molecular mass, inhibitor of fibroblast growth factor. Neuroscience Letters 2011; 491(-1-):1-7. >>> Dobesilate; PBS; CSF/CNS (intratumoral); Rat; 2004; 27 days; Controls received mp w/ vehicle; cancer (glioma); Compound, also known as (2,5-dihydroxyphenyl-sulfonate or 2,5DHPS) is an FGF inhibitor; chemotherapeutic.

Q0715 Shibata,M.A., Morimoto,J., Shibata,E., Kurose,H., Akamatsu,K., Li,Z.L., Kusakabe,M., Ohmichi,M., Otsuki,Y. Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC CANCER 2010; 10(-;-):U1-U14. >>> Raloxifene; DMSO; ethanol; SC; Mice; 2002; 6 weeks; Animal info (female, 6 wks old, BALB/c); long-term study; pumps replaced every other week; cancer (metastatic breast cancer); stress/adverse reaction: "one animal died from an overdose of anesthesia when the osmotic mini-pumps were changed" (see pg. 7 of 14); raloxifene is a novel selective estrogen receptor modulator; chemotherapeutic.

Q0501 Donawho,C.K., Luo,Y., Luo,Y.P., Penning,T.D., Bauch,J.L., Bouska,J.J., Bontcheva-Diaz,V.D., Cox,B.F., DeWeese,T.L., Dillehay,L.E., Ferguson,D.C., Ghoreishi-Haack,N.S., Grimm,D.R., Guan,R., Han,E.K., Holley-Shanks,R.R., Hristov,B., Idler,K.B., Jarvis,K., Johnson,E.F., Kleinberg,L.R., Klinghofer,V., Lasko,L.M., Liu,X.S., Marsh,K.C., McGonigal,T.P., Meulbroek,J.A., Olson,A.M., Palma,J.P., Rodriguez,L.E., Shi,Y., Stavropoulos,J.A., Tsurutani,A.C., Zhu,G.D., Rosenberg,S.H., Giranda,V.L., Frost,D.J. ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research 2007; 13(-9-):2728-2737. >>> ABT-888; Saline; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; dose-response (pg 2732, fig. 2); cancer; animal info (C57BL/6, SCID); chemotherapeutic; "ABT-888 administered... via (minipump) not only potentiated cyclophosphamide... but also caused tumor regression, whereas the cyclophosphamide monotherapy only slightly delayed tumor growth." pg 2733.

Q0420 Peng,S.C., Lai,Y.T., Huang,H.Y., Huang,H.D., Huang,Y.S. A novel role of CPEB3 in regulating EGFR gene transcription via association with Stat5b in neurons. NUCLEIC ACIDS RESEARCH 2010; 38(-21-):7446-7457. >>> Endothelial growth factor, recomb.; gefitinib; DMSO; CSF, artificial; BSA; CSF/CNS; Mice; 1004; 14 days; Controls received mp w/ vehicle; animal info (8 wks old, male, C57BL/6J); behavioral testing (Morris water maze test); gefitinib is a chemotherapeutic.

Q0306 Norrby,K., Nordenhem,A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118(-12-):949-957. >>> Dalteparin; epirubicin; Saline; SC; Rat; 2002; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague-Dawley, 6-7 wks old, 218-223 g.); cancer; multiple pumps per animal (2); dalteparin is a low-molecular-weight heparin; epirubicin is a chemotherapeutic.

P9819 Savai,R., Langheinrich,A.C., Schermuly,R.T., Pullamsetti,S.S., Dumitrascu,R., Traupe,H., Rau,W.S., Seeger,W., Grimminger,F., Banat,A. Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. NEOPLASIA 2009; 11(-1-):48-56. >>> Bevacizumab; IV (jugular); Mice (nude); 2002; 14 days; Controls received mp w/ distilled water; animal info (female, C57BL/6, 5-7 wks old, BALB/c, nu/nu, 7-8 wks old); pump implated IP; bevacizumab is a anti-VEGF antibody; "This delivery (using ALZET pumps) mimics local delivery of antivascular agents and can be used effectively alone or in combination with cytotoxic chemotherapy for site-specific drug delivery for lung cancer treatment. As expected, continuous infusion of bevacizumab decreased lung tumor volume and tumor perfusion, with an added survival advantage compared to the untreated group." pg 55; cancer (lung); antibody.

P0708 Maltese,W.A., Defendini,R., Green,R.A., Sheridan,K.M., Donley,D.K. Supression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J.Clin.Invest. 1985; 76(--):1748-1754. >>> Mevinolin; Glycerol; HCl; SC; mice; 2001; 7 days or 24 hours; cancer chemotherapy; verification of 7 day mp functionality; stress/adverse reaction (inflam., necrosis, sc edema at exit port) presumably due to high local drug levels.

P0533 Bartholeyns,J., Mamont,P., Casara,P. Antitumor properties of (2R,5R)-6-heptyne-2,5-diamine, a new potent enzyme-activated irreversible inhibitor of ornithine decarboxylase, in rodents. Cancer Res. 1984; 44(--):4972-4977. >>> MDL 72175; Saline; SC; rat; 18 days; mp model not stated; comparison of MDL po in drinking water vs. mp infusion; cancer chemotherapy.

top of page

18. TIMP

P5373 Takahashi,M., Fukami,S., Iwata,N., Inoue,K., Itohara,S., Itoh,H., Haraoka,J., Saido,T.C. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacological Research 2002; 46(-2-):155-163. >>> TIMP-1; TIMP-2; PBS; CSF/CNS (intratumoral); Rat; 2002; 3, 7, or 14 days; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by immunohistochemistry of agents; cancer; enzyme inhibitor; ALZET brain infusion kit used; MMP inhibitors (tissue inhibitors of metalloprotease = TIMP); rat glioma model.

top of page

19. Vinblastine

P8780 Albertsson,P., Lennernaes,B., Norrby,K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncologica 2008; 47(-2-):293-300. >>> Vinblastine sulfate; Saline, physiological; SC; Rat; 2001; 2ML1; 6-10 days; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 296); cancer; animal info (male, Sprague Dawley, 217-219g.).

P8474 Klement,G., Baruchel,S., Rak,J., Man,S., Clark,K., Hicklin,D.J., Bohlen,P., Kerbel,R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation 2000; 105(-8-):15-24. >>> Vinblastine sulfate; Saline; SC; Mice (SCID); 3 weeks; Controls received IP injections; comparison of IP injections vs. mp; no stress (see pg. R19); cancer (neuroblastoma); toxicology; animal info (SCID, 4-6 weeks old, 15-20 grams); IP bolus given at start of mp treatment.

P4575 van Asperen,J., van Tellingen,O., Schinkel,A.H, Beijnen,J.H. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-Glycoprotein.. The Journal of Pharmacology and Experimental Therapeutics. 1999; 289(-1-):329-333. >>> Vinblastine; Dextrose; SC; Mice; 2001; 96 hours; Functionality of mp verified by plasma levels; half-life (p. 330); antineoplastic.

P4402 Vu,D.-D., Daniel,N.G., Nanci,A. In vivo model for the experimental manipulation of calcified tissues: A surgical approach for accessing the odontogenic organ and associated tissues of the rat incisor;. Journal of Histochemistry and Cytochemistry 1999; 47(-3-):323-336. >>> Vinblastine sulfate; fetuin-gold; BSA, dinitrophenol-tagged-; Saline, physiological; Bone; Rat; 1003D; 2001D; 1, 3 days; controls received mp with vehicle; tissue perfusion (alveolar bone); "Minipumps...are advantageous compared to microinjection because they can deliver, in a controlled and continuous manner, relatively large amounts of experimental agents through a bony window" p. 325;.

P1935 Sivolapenko,G.B., Moreno,C., Smith,W., Corvalan,J., Ritter,M.A., Epenetos,A.A. Xenogenic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate. Br.J.Cancer 1991; 64(--):281-287. >>> Vinblastine; SC; rabbit; 2ML1; no duration posted; cancer.

top of page

20. Vincristine

P8148 Honore,P., Donnelly-Roberts,D., Namovic,M.T., Hsieh,G., Zhu,C.Z., Mikusa,J.P., Hernandez,G., Zhong,C.M., Gauvin,D.M., Chandran,P., Harris,R., Medrano,A.P., Carroll,W., Marsh,K., Sullivan,J.P., Faltynek,C.R., Jarvis,M.F. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2- dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. Journal of Pharmacology and Experimental Therapeutics 2006; 319(-3-):1376-1385. >>> Vincristine sulfate; IV (jugular); Rat; 2002; 14 days; Animal info (male, Sprague-Dawley, 200-300g.); mp primed overnight; chemotherapy-induced neuropathic pain model.

P7125 Lynch,JJ III, Wade,C.L., Mikusa,J.P., Decker,M.W., Honore,P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. European Journal of Pharmacology 2005; 509(-1-):43-48. >>> Vincristine sulfate; Saline, physiological; IV (external jugular); Rat; 2002; 1-3 weeks; Cancer; mp primed overnight.

P7066 Lynch,JJ III, Wade,C.L., Zhong,C.M.M., Mikusa,J.P., Honore,P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 2004; 110(-1-2-):56-63. >>> Vincristine sulfate; Saline, physiological; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ vehicle; no stress (see pg. 58); cancer; mp primed overnight.

P6168 Luo,Z.D., Calcutt,N.A., Higuera,E.S., Valder,C.R., Song,Y.H., Svensson,C.I., Myers,R.R. Injury type-specific calcium channel alpha 2 delta-1subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. Journal of Pharmacology and Experimental Therapeutics 2002; 303(-3-):1199-1205. >>> Vincristine; Saline, sterile; IV (jugular); Rat; 2002; 2 weeks; Behavioral study.

P4213 Ruigt,G.S.F., den Brok,M.H.C. Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine. Cancer Chemother.Pharmacol. 1995; 36(--):530-535. >>> Vincristine sulfate; Saline; CSF/CNS (sciatic nerve); rat; 2002; 1007D; 1 week; controls received mp w/vehicle; comparison of i.p. injections vs local infusion via mp; stress/adverse reaction: scar tissue; cytostatic agent; cancer.

top of page

Looking for references? We can help!

ALZET will perform a custom bibliography search for you! ALZET pumps have been used to deliver hundreds of different compounds, including proteins and peptides, in a myriad of different experimental applications. We have recently updated our database, which now contains over 12,000 references that can help you guide your research project!

Order the ALZET SurgicalImplantation Video

Researchers are saying ...

“Considering the secretion rate of CSF in rats (120 to 320 ul/h), this low rate of infusion – 0.5µl/h – was not likely to affect CSF pressure.” Wang et al., Hypertension 2002;40:96-100.

ALZET® Osmotic Pumps - Research Applications.

References on the Administration of Chemotherapeutic Agents Using ALZET^® Osmotic Pumps

1. Actinomycin

2. Angiostatin

3. Ara-C

4. Azacytidine

5. Bleomycin

6. CDDP

7. Carboplatin

8. Cisplatin

9. Cyclophosphamide

10. Doxorubicin

11. Endostatin

12. Etoposide

13. Fluorouracil

14. Marimastat

15. Methotrexate

16. Mitomycin

17. Other Chemotherapeutics

18. TIMP

19. Vinblastine

20. Vincristine

Looking for references? We can help!

Researchers are saying ...

ALZET Customer Service-

ALZET® Osmotic Pumps - Research Applications.

References on the Administration of Chemotherapeutic Agents Using ALZET® Osmotic Pumps

1. Actinomycin

2. Angiostatin

3. Ara-C

4. Azacytidine

5. Bleomycin

6. CDDP

7. Carboplatin

8. Cisplatin

9. Cyclophosphamide

10. Doxorubicin

11. Endostatin

12. Etoposide

13. Fluorouracil

14. Marimastat

15. Methotrexate

16. Mitomycin

17. Other Chemotherapeutics

18. TIMP

19. Vinblastine

20. Vincristine

Looking for references? We can help!

Researchers are saying ...

ALZET Customer Service-

References on the Administration of Chemotherapeutic Agents Using ALZET^® Osmotic Pumps